Highlights Ipsen

Equities

IPN

FR0010259150

Real-time Euronext Paris Other stock markets 04:55:48 2024-04-30 am EDT			5-day change	1st Jan Change
112.6 ^EUR	+0.09%		+1.08%	+4.36%

Apr. 24	IPSEN : Better-than-expected Q1; guidance unchanged
Apr. 24	Transcript : Ipsen S.A., Q1 2024 Sales/ Trading Statement Call, Apr 24, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IPSEN : Better-than-expected Q1; guidance unchanged	Apr. 24
Ipsen Teams Up with Skyhawk Therapeutics on Study of RNA Modulator for Rare Neurological Diseases	Apr. 22	MT
Ipsen: collaboration agreement with Skyhawk	Apr. 22	CF
Ipsen and Skyhawk Therapeutics Announces RNA Targeting Research Collaboration in Rare Neurological Diseases	Apr. 22	CI
Ipsen: worldwide licensing agreement with Sutro Biopharma	Apr. 02	CF
Ipsen Signs Licensing Deal for Cancer-targeting Antibody Conjugate with Sutro Biopharma	Apr. 02	MT
IPSEN : Ipsen’s underlying fundamentals remain promising	Mar. 13
Ipsen: new indication approved in pancreatic cancer	Feb. 14	CF
Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval	Feb. 13	DJ
Ipsen?s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA	Feb. 13	CI
Ipsen S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
IPSEN : In line Q4 sales; lower-than-expected 2024 guidance	Feb. 08
Ipsen: 13% drop in annual EPS	Feb. 08	CF
Ipsen presents positive data for Cabometyx	Jan. 23	CF
Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024	Jan. 22	CI
Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC	Dec. 07	CI
Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial	Nov. 13	CI
Ipsen S.A. Confirms Sales Guidance for the Fiscal Year 2023	23-10-26	CI
Tribal Group recommends GBP172 million takeover from Ellucian	23-10-05	AN
Ipsen Updates on QM-1114 Regulatory Process	23-10-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

IPSEN : Better-than-expected Q1; guidance unchanged

April 24, 2024 at 10:50 am EDT